Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
469.27
-1.04 (-0.22%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Stock Plummets 13% After Discontinuing VX-993 Despite Q2 Earnings Beat
↗
August 04, 2025
Vertex Q2 2025 earnings beat estimates, but stock dropped 13% after discontinuing acute pain drug VX-993. Focus remains on CF and other key programs.
Via
Chartmill
Topics
Earnings
Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat
↗
August 04, 2025
Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.
Via
Investor's Business Daily
Topics
ETFs
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%
August 04, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full...
Via
StockStory
Topics
Earnings
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
August 04, 2025
Via
Benzinga
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus
↗
August 04, 2025
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics.
Via
Benzinga
What To Expect From Vertex Pharmaceuticals’s (VRTX) Q2 Earnings
August 02, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
Economy
World Trade
3 Unstoppable Stocks to Buy in August
↗
August 02, 2025
Here are hot stocks to buy in a hot month.
Via
The Motley Fool
Topics
Intellectual Property
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
↗
August 01, 2025
Via
Benzinga
Examining the Future: Vertex Pharmaceuticals's Earnings Outlook
↗
August 01, 2025
Via
Benzinga
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
↗
August 01, 2025
These growth stocks have plenty of room to run.
Via
The Motley Fool
The 3 Things That Matter for Vertex Pharmaceuticals Now
↗
July 28, 2025
Some of these developments could improve the company's prospects.
Via
The Motley Fool
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
↗
July 22, 2025
Via
The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
↗
July 21, 2025
Via
The Motley Fool
3 Top Growth Stocks to Buy in the Second Half of 2025
↗
July 19, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
↗
July 18, 2025
Via
Benzinga
3 Cash-Burning Stocks Walking a Fine Line
July 15, 2025
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...
Via
StockStory
Topics
Bankruptcy
Economy
My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)
↗
July 14, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Energy
World Trade
The Best Stocks to Invest $1,000 in Right Now
↗
July 12, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
↗
July 12, 2025
With just a little bit of a deeper look, these businesses are positioned for long-term growth.
Via
The Motley Fool
Motley Fool Co-Founder David Gardner Reviews Stock Picks
↗
July 11, 2025
Via
The Motley Fool
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
↗
July 08, 2025
Via
The Motley Fool
Topics
Stocks
3 No-Brainer Stocks to Buy in July
↗
July 07, 2025
Via
The Motley Fool
The Best Stocks to Invest $1,000 In Right Now
↗
July 05, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU
↗
July 01, 2025
Vertex announced on Tuesday that eligible patients in Ireland, Denmark, and Germany will have access to Alyftrek shortly after receiving regulatory approval from the relevant authorities.
Via
Stocktwits
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
↗
June 30, 2025
Via
Benzinga
How Do Investors Really Feel About Vertex Pharmaceuticals?
↗
June 27, 2025
Via
Benzinga
3 S&P 500 Stocks with Mounting Challenges
June 27, 2025
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Vertex Pharmaceuticals Unusual Options Activity
↗
June 26, 2025
Via
Benzinga
3 Unpopular Stocks Facing Headwinds
June 23, 2025
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
63
64
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today